Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic hematopoietic stem cells used in the context of the REAL-GREFFE observational study (NCT03357172) conducted at Central Hospital (Hôpital Brabois), Nancy, France. These cells are obtained from matched related or unrelated donors and are used as a cellular therapy for patients with hematologic malignancies or other disorders requiring stem cell transplantation. The study specifically investigates the immune cell composition of the graft—including effector T cells, regulatory T cells (Tregs), invariant natural killer T (iNKT) cells, and myeloid-derived suppressor cells (MDSC)—and correlates these subsets with post-transplant outcomes such as graft-versus-host disease (GVHD), disease relapse, and infections. The therapy is often administered following conditioning regimens that may include anti-lymphocyte globulin (ATLG or ATG) for GVHD prophylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic hematopoietic stem cells-Central Hospital, Nancy, France.